Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)

DRUG2 trials

Sponsors

Shanghai Public Health Clinical Center, UBATEC

Conditions

Acquired Immunodeficiency SyndromeHIVHIV-1

Phase 4

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

Not yet recruitingNCT05493969

Shanghai Public Health Clinical CenterAcquired Immunodeficiency Syndrome

Start: 2022-08-31End: 2026-06-30Target: 100Updated: 2022-08-09

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

RecruitingNCT06967753

UBATECHIV, HIV-1

Start: 2025-07-31End: 2027-02-28Target: 50Updated: 2025-09-12

Related Papers

Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity.

2026-05-20